Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6164]

Targeting strategy may open door to better cancer drug delivery

Targeting strategy may open door to better cancer drug delivery

Study suggests new combination treatment against relapsed head and neck cancer

Study suggests new combination treatment against relapsed head and neck cancer

ASCO 2018: Interim results from clinical trial of immunotherapy for glioblastoma show significant clinical benefit

ASCO 2018: Interim results from clinical trial of immunotherapy for glioblastoma show significant clinical benefit

ASCO 2018: First comparison of two prostate cancer therapies finds vastly different cost-effectiveness between strategies

ASCO 2018: First comparison of two prostate cancer therapies finds vastly different cost-effectiveness between...

New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments

New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments

ASCO 2018: Taking acid-reducing medicine with aspirin offers moderate benefits in patients with Barrett’s oesophagus

ASCO 2018: Taking acid-reducing medicine with aspirin offers moderate benefits in patients with Barrett’s...

ASCO 2018: Chemotherapy regimen extends life by nearly twenty months for people with pancreatic cancer

ASCO 2018: Chemotherapy regimen extends life by nearly twenty months for people with pancreatic cancer

ASCO 2018: Heated abdominal chemotherapy not beneficial in patients with advanced colorectal cancer

ASCO 2018: Heated abdominal chemotherapy not beneficial in patients with advanced colorectal cancer

ASCO 2018: Pre-operative chemotherapy with radiation may help people with pancreatic cancer live longer

ASCO 2018: Pre-operative chemotherapy with radiation may help people with pancreatic cancer live longer

ASCO 2018: Erdafitinib shows promise in urothelial cancer patients with specific mutations

ASCO 2018: Erdafitinib shows promise in urothelial cancer patients with specific mutations

More from ecancer